Swiss National Bank Has $5.83 Million Position in Ultragenyx Pharmaceutical Inc. $RARE

Swiss National Bank lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 161,052 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the period. Swiss National Bank owned 0.17% of Ultragenyx Pharmaceutical worth $5,832,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 76.2% in the first quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 323 shares during the period. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at $57,000. Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical during the first quarter valued at $59,000. GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $82,000. Finally, Quarry LP bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at about $84,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on RARE shares. Morgan Stanley cut their price target on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, July 14th. Canaccord Genuity Group decreased their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Cantor Fitzgerald reduced their price target on Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an “overweight” rating for the company in a research report on Wednesday, August 6th. William Blair started coverage on Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price objective on the stock. Finally, Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research note on Monday, July 14th. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $81.50.

Ultragenyx Pharmaceutical Stock Performance

RARE opened at $29.70 on Tuesday. The firm has a market cap of $2.86 billion, a P/E ratio of -5.37 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a 52-week low of $25.81 and a 52-week high of $60.37. The business’s fifty day moving average is $32.37 and its 200-day moving average is $36.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) EPS for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%. The business’s quarterly revenue was up 13.2% on a year-over-year basis. During the same period last year, the company earned ($1.52) earnings per share. On average, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm’s stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares in the company, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.